{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:48Z","timestamp":1791389028093,"version":"4.3.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"DOI":"10.7759\/cureus.104529","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:34:27Z","timestamp":1772447667000},"source":"Crossref","is-referenced-by-count":1,"title":["Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review"],"prefix":"10.7759","author":[{"given":"Ben C","family":"Hane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurav","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31674","article-title":"Adult leukemia survival trends in the United States by subtype: a population-based registry study of 370,994 patients diagnosed during 1995-2009","volume":"124","author":"Bailey C","year":"2018","unstructured":"Bailey C, Richardson LC, Allemani C, et al.. Adult leukemia survival trends in the United States by subtype: a population-based registry study of 370,994 patients diagnosed during 1995-2009. Cancer. 2018, 124:3856-67. 10.1002\/cncr.31674","journal-title":"Cancer"},{"key":"ref2","article-title":"Chronic Lymphocytic Leukemia","author":"Mukkamalla SKR","year":"2025","unstructured":"Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic Lymphocytic Leukemia. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.979411","article-title":"Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy","volume":"56","author":"Jamroziak K","year":"2015","unstructured":"Jamroziak K, Tadmor T, Robak T, Polliack A. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma. 2015, 56:1949-58. 10.3109\/10428194.2014.979411","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf O","year":"2021","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J, et al.. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021, 35:169-76. 10.1038\/s41375-020-0797-x","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060943","article-title":"Updates on the treatment of Richter\u2019s syndrome, including novel combination approaches","volume":"17","author":"Jain T","year":"2025","unstructured":"Jain T, Heyman B. Updates on the treatment of Richter\u2019s syndrome, including novel combination approaches. Cancers (Basel). 2025, 17:14-6. 10.3390\/cancers17060943","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181108","article-title":"Pirtobrutinib in Richter Transformation: updated efficacy and safety results with 18-month median survival follow-up from the phase 1\/2 BRUIN study","volume":"142","author":"Wierda WG","year":"2023","unstructured":"Wierda WG, Shah NN, Cheah CY, et al.. Pirtobrutinib in Richter Transformation: updated efficacy and safety results with 18-month median survival follow-up from the phase 1\/2 BRUIN study. Blood. 2023, 142:1737. 10.1182\/blood-2023-181108","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01274-6","article-title":"CLL-280 Epcoritamab induces deep responses in patients with Richter transformation (RT): primary results from the EPCORE CLL-1 trial","volume":"24","author":"Kater AP","year":"2024","unstructured":"Kater AP, Janssens A, Eradat H, et al.. CLL-280 Epcoritamab induces deep responses in patients with Richter transformation (RT): primary results from the EPCORE CLL-1 trial. Clin Lymphoma Myeloma Leuk. 2024, 24:350-1. 10.1016\/S2152-2650(24)01274-6","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080764","article-title":"Non-covalent BTK inhibitors-the New BTKids on the Block for B-cell malignancies","volume":"11","author":"Lewis KL","year":"2021","unstructured":"Lewis KL, Cheah CY. Non-covalent BTK inhibitors-the New BTKids on the Block for B-cell malignancies. J Pers Med. 2021, 11:32-4. 10.3390\/jpm11080764","journal-title":"J Pers Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200339","article-title":"Lisocabtagene maraleucel (liso-cel) combined with Ibrutinib (ibr) for patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1\/2 Transcend CLL 004 study","volume":"144","author":"Wierda WG","year":"2024","unstructured":"Wierda WG, Dorritie K, Gauthier J, et al.. Lisocabtagene maraleucel (liso-cel) combined with Ibrutinib (ibr) for patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1\/2 Transcend CLL 004 study. Blood. 2024, 144:887. 10.1182\/blood-2024-200339","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T Cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik M","year":"2019","unstructured":"Mhibik M, Wiestner A, Sun C. Harnessing the effects of BTKi on T Cells for effective immunotherapy against CLL. Int J Mol Sci. 2019, 21:26-8. 10.3390\/ijms21010068","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005571","article-title":"Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL","volume":"6","author":"Yano M","year":"2022","unstructured":"Yano M, Nunes J, Mo X, Rogers KA, Woyach JA, Byrd JC, Muthusamy N. Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL. Blood Adv. 2022, 6:5440-8. 10.1182\/bloodadvances.2021005571","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long M","year":"2017","unstructured":"Long M, Beckwith K, Do P, et al.. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017, 127:3052-64. 10.1172\/JCI89756","journal-title":"J Clin Invest"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118333","article-title":"Ibrutinib-based therapy improves anti-tumor T cell killing function allowing effective pairing with anti-PD-L1 immunotherapy compared to traditional FCR chemoimmunotherapy; implications for therapy and correlative immune functional data from the phase III E1912 trial","volume":"132","author":"Papazoglou D","year":"2018","unstructured":"Papazoglou D, Lesnick CE, Wang V, Kay NE, Shanafelt TD, Ramsay A. Ibrutinib-based therapy improves anti-tumor T cell killing function allowing effective pairing with anti-PD-L1 immunotherapy compared to traditional FCR chemoimmunotherapy; implications for therapy and correlative immune functional data from the phase III E1912 trial. Blood. 2018, 132:236. 10.1182\/blood-2018-99-118333","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik M","year":"2023","unstructured":"Mhibik M, Gaglione EM, Eik D, et al.. Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv. 2023, 7:4089-101. 10.1182\/bloodadvances.2022009517","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450426-bruton-tyrosine-kinase-inhibition-in-combination-with-bispecific-antibodies-for-richters-syndrome-a-report-of-two-cases-and-mini-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:34:28Z","timestamp":1772447668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450426-bruton-tyrosine-kinase-inhibition-in-combination-with-bispecific-antibodies-for-richters-syndrome-a-report-of-two-cases-and-mini-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.104529","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}